These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1008 related items for PubMed ID: 21601352

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam.
    Roobol MJ, Zhu X, Schröder FH, van Leenders GJ, van Schaik RH, Bangma CH, Steyerberg EW.
    Eur Urol; 2013 Apr; 63(4):627-33. PubMed ID: 22841675
    [Abstract] [Full Text] [Related]

  • 23. Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer.
    Roobol MJ, Kranse R, Bangma CH, van Leenders AG, Blijenberg BG, van Schaik RH, Kirkels WJ, Otto SJ, van der Kwast TH, de Koning HJ, Schröder FH, ERSPC Rotterdam Study Group.
    Eur Urol; 2013 Oct; 64(4):530-9. PubMed ID: 23759326
    [Abstract] [Full Text] [Related]

  • 24. 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Schröder FH, Raaijmakers R, Postma R, van der Kwast TH, Roobol MJ.
    J Urol; 2005 Aug; 174(2):489-94; discussion 493-4. PubMed ID: 16006878
    [Abstract] [Full Text] [Related]

  • 25. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
    Calais da Silva FE, Bono AV, Whelan P, Brausi M, Marques Queimadelos A, Martin JA, Kirkali Z, Calais da Silva FM, Robertson C.
    Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
    [Abstract] [Full Text] [Related]

  • 26. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
    Hattangadi JA, Chen MH, D'Amico AV.
    BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Screening for prostate cancer: updated experience from the Tyrol study.
    Horninger W, Berger A, Pelzer A, Klocker H, Oberaigner W, Schönitzer D, Severi G, Robertson C, Boyle P, Bartsch G.
    Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
    [Abstract] [Full Text] [Related]

  • 29. Prostate specific antigen testing and digital rectal examination before and during a randomized trial of screening for prostate cancer: European randomized study of screening for prostate cancer, Rotterdam.
    Beemsterboer PM, de Koning HJ, Kranse R, Trienekens PH, van der Maas PJ, Schröder FH.
    J Urol; 2000 Oct; 164(4):1216-20. PubMed ID: 10992369
    [Abstract] [Full Text] [Related]

  • 30. Low all-cause mortality in the volunteer-based Rotterdam section of the European randomised study of screening for prostate cancer: self-selection bias?
    Otto SJ, Schröder FH, de Koning HJ.
    J Med Screen; 2004 Oct; 11(2):89-92. PubMed ID: 15153324
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Raaijmakers R, Wildhagen MF, Ito K, Pàez A, de Vries SH, Roobol MJ, Schröder FH.
    Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Extent of prostate-specific antigen contamination in the Spanish section of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Luján M, Páez A, Pascual C, Angulo J, Miravalles E, Berenguer A.
    Eur Urol; 2006 Dec; 50(6):1234-40; discussion 1239-40. PubMed ID: 16704893
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
    Roobol MJ, Roobol DW, Schröder FH.
    Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
    Roobol MJ, Kranse R, de Koning HJ, Schröder FH.
    Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Critical assessment of prebiopsy parameters for predicting prostate cancer metastasis and mortality.
    van Leeuwen PJ, van den Bergh RC, Wolters T, Zhu X, Bul M, Schröder FH, Bangma CH, Roobol MJ.
    Can J Urol; 2011 Dec; 18(6):6018-24. PubMed ID: 22166329
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 51.